

Morphine Equivalent Dose (MED)/Opioid Medication Supplemental Information Form

Effective May 1, 2024

You can complete this form and fax it to the Pharmacy Department at 217-902-9798, or fill out only Section D of this form and attach it as additional documentation to the Pharmacy Preauthorization Request Form when you request preauthorization through the FirstCarolinaCare Tapestry Login for providers. If you have questions, call 1-800-481-1092, option 4.

Section A—Member Information										
Today's Date:		First Name:				Last Name:				
Member ID #:		Date of Birth:								
Primary Insurance:										
Is the requested medication new Is this patient currently hospitalized	☐ or a contin d? ☐ Yes ☐	uation of t	therapy □ ? If s	50, V	what is the start date	∍?				
Section B—Provider Information	1									
First Name:	Last I			ast Name:						
Address:					ity:		State:	ZIP:		
Phone:	Fax:				NPI:	NPI:				
Specialty:		Email:				Office Contact Name:				
Section C—Clinical Information										
Include all opioid drugs the men	nber is curre	ently usir	ng.							
Drug Name	Drug Name Streng		th Quantity		Days Supply	Directions for Use				
Diagnosis (Please provide specific details):				IC	D-10 code(s):					
□ Request is not urgent□ Req□ I certify that the information prov	uest is urgen ⁄ided is true		rate to the best	of r	my knowledge.					
Prescriber's Signature				Date						

Section D—Treatment Details Please read carefully and complete ALL fields that apply. Refer to this document for MED conversion factors. Supporting chart documentation is required.							
1. Cancer Treatment, Sickle Cell Disease and Hospice							
Is member receiving opioid due to cancer treatment?							
Is member receiving opioid due to sickle cell disease?							
Is member receiving hospice services? ☐ Yes ☐ No							
Approval is for 12 months. Note: Completion of remaining sections is NOT required if treating cancer, sickle cell disease or hospice-enrolled patients.							
2. All Opioid Claims Unrelated to Cancer, Sickle Cell Disease or Hospice Care*† (This section is required for all requests)							
Has member used opioid medications in the previous 120 days? ☐ Yes ☐ No If Yes, list drug names, doses and dates of use							
If No, please submit documentation of medical necessity for an opioid naive patient to receive opioid therapy for greater than seven days. Is member using a benzodiazepine concurrently with opioid treatment? ☐ Yes ☐ No If Yes, list drug name, dose and dates of use							
If Yes, has provider reviewed this contraindication and determined that concurrent use of an opioid is needed even with the associated risk? □ Yes □ No							
Has member been educated on the availability and proper use of immediate opioid antagonist therapy (Narcan)? ☐Yes ☐No Has provider seen member in the last three months? ☐ Yes ☐ No Date of last visit							
Has provider done a full evaluation of member's pain and identified any potential underlying causes? ☐Yes ☐No Has provider evaluated non-pharmacological therapies? ☐ Yes ☐ No Please list							
Has member been escalated to the requested dose? ☐ Yes ☐ No Has provider discussed the risks of opioid treatment with member? ☐ Yes ☐ No							
3. Opioid Therapies with a Total Daily Morphine Equivalence Dose (MED) of 100mg or More, Unrelated to Cancer, Sickle Cell Disease or Hospice Care*†							
Does provider have a pain contract with member restricting the prescribing of pain medication to no more than two providers? No lf applicable, list other provider(s)							
Does provider order a urine toxicology screen for member at least annually? Yes No Please attach most recent test results. Has provider reviewed member's state prescription monitoring program at least once in the last three months? Yes No In addition to the above, provide a treatment plan including the long-term goals of treatment as well as a tapering plan for member to discontinue pain medication or achieve pain control at a level below 100mg MED. If no tapering plan exists, indicate why							
If the opioid drug will treat post-operative pain, is there a plan to taper pain medications?							
4. Long-Acting Opioids for New Starts to Therapy, Unrelated to Cancer, Sickle Cell or Hospice Care*†							
Does provider have a pain contract with member restricting the prescribing of pain medication to no more than two providers? Yes No If applicable, list other provider(s)							
Does provider order a urine toxicology screen for member at least annually? □Yes □No Please attach most recent test results. Has provider reviewed member's state prescription monitoring program at least once in the last three months? □Yes □No Has member been on an equivalent of at least 60mg of morphine per day for at least one week? □Yes □No Does the member have a documented diagnosis of pain severe enough to require daily, around-the-clock, long-term opioid treatment? □Yes □No							
If the long-acting drug will treat post-operative pain, is there a plan to taper pain medications? Yes No Attention: Long-acting opioid medications are not recommended for treating post-operative pain. Non-opioid analgesics and immediate-release opioids are recommended for short-term use.							
5. Tramadol Extended-Release (Generic Ultram ER) Unrelated to Cancer, Sickle Cell Disease or Hospice Care*†							
Does the member have a history of failure, contraindication or intolerance to a 30-day trial of tramadol immediate-release (IR)?							
6. Nucynta Immediate-Release (IR) Unrelated to Cancer, Sickle Cell Disease or Hospice Care*†							
Does member have a history of failure, contraindication or intolerance to a 30-day trial of tramadol IR or a Tier 1 short-acting opioid (including but not limited to hydrocodone, oxycodone and morphine)? Yes No							

^{*}Approval for chronic pain treatment unrelated to cancer, sickle cell disease or hospice care: six months at current calculated MED at time of request

[†]Approval for short-term post-operative pain treatment: one month at calculated MED level